HWAM
CHRS icon

Hennion & Walsh Asset Management’s Coherus Oncology CHRS Stock Holding History

Hennion & Walsh Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-132,137
Closed -$1.27M – 771
2022
Q3 		$1.27M Sell
132,137
-7,465
-5% -$75.5K 0.08% 274
2022
Q2 		$1.01M Sell
139,602
-6,487
-4% -$56.4K 0.06% 308
2022
Q1 		$1.89M Sell
146,089
-5,258
-3% -$66.9K 0.1% 226
2021
Q4 		$2.42M Sell
151,347
-13,838
-8% -$242K 0.12% 214
2021
Q3 		$2.65M Sell
165,185
-3,641
-2% -$53.4K 0.14% 206
2021
Q2 		$2.33M Buy
168,826
+23,307
+16% +$330K 0.12% 220
2021
Q1 		$2.13M Buy
+145,519
New +$2.47M 0.13% 219

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hennion & Walsh Asset Management's CHRS Position: Q4 2022 in Review

Hennion & Walsh Asset Management sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 132,137 shares — an estimated $1.27M sold.

Hennion & Walsh Asset Management first reported a position in CHRS in Q1 2021 and held it in 7 quarters. The position peaked at $2.65M in Q3 2021. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Hennion & Walsh Asset Management reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 132,137 Coherus Oncology shares in Q4 2022, an estimated $1.27M.
  • Hennion & Walsh Asset Management first reported a position in Coherus Oncology in Q1 2021 and held it in 7 quarters.
  • Hennion & Walsh Asset Management's Coherus Oncology position peaked at $2.65M in Q3 2021.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2022, filed 12 Jan 2023.